Pharvaris Forecasted to Earn Q4 2024 Earnings of ($0.54) Per Share (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS) – Analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for Pharvaris in a research note issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.54) for the quarter, up from their prior estimate of ($0.55). The consensus estimate for Pharvaris’ current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Pharvaris’ FY2025 earnings at ($2.15) EPS.

A number of other analysts have also recently issued reports on the stock. JMP Securities lifted their target price on shares of Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research note on Thursday, April 11th. Morgan Stanley decreased their price objective on shares of Pharvaris from $35.00 to $34.00 and set an “overweight” rating for the company in a report on Monday. Finally, Wedbush restated an “outperform” rating and set a $35.00 target price on shares of Pharvaris in a report on Thursday, April 11th.

Pharvaris Stock Down 13.1 %

Shares of PHVS stock opened at $18.42 on Thursday. Pharvaris has a fifty-two week low of $7.93 and a fifty-two week high of $33.00. The stock’s 50-day moving average is $24.20 and its two-hundred day moving average is $23.26.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Qube Research & Technologies Ltd acquired a new stake in Pharvaris in the 3rd quarter valued at about $54,000. UBS Group AG bought a new position in Pharvaris in the 4th quarter valued at $32,000. Tower Research Capital LLC TRC acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $26,000. Bank of America Corp DE raised its position in shares of Pharvaris by 1,054.4% during the first quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock worth $105,000 after acquiring an additional 5,272 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Pharvaris during the fourth quarter valued at $240,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).